Using gut health to improve seizure control in CDKL5 disorder
Part of Brain & nervous system, Mental health clinical trials.
This study tests whether changing the gut environment can help reduce seizures in children and adults with CDKL5 deficiency disorder, a rare genetic condition that causes hard-to-control seizures. It is designed for people whose seizures aren't controlled by medicine and who do not have other gut issues or special diets.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child must have a confirmed diagnosis of CDKL5 deficiency disorder with a specific gene change.
- Seizures must not be fully controlled by current medications (drug-resistant).
- A caregiver must be available to help with the study tasks.
- No chronic gut problems like food allergies or celiac disease.
- No special diets (for example, keto or gluten-free) and no feeding tube (PEG).
- No antibiotics or probiotics in the past month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for anyone diagnosed with CDKL5 disorder who can be seen at participating clinics or is already listed in an international CDKL5 registry. The goal is to help researchers better understand the condition and support future research.
This trial studies how well a ketogenic diet works for children with hard-to-treat epilepsy or certain other diseases. It aims to see if the diet improves quality of life.
This study looks at how the gut and brain talk to each other in people with epilepsy, especially when seizures are hard to control. It may help find new ways to treat epilepsy by focusing on the gut.
This trial tests whether daily warm baths at home can help reduce seizures in children with CDKL5 deficiency disorder—a rare genetic condition that causes hard-to-control epilepsy. The study wants to see if heat therapy is safe and actually works for these children.
This trial tests ganaxolone, a seizure medicine, to see if it can reduce seizures in young children with CDKL5 deficiency. Participants get the real medicine or a placebo, and families help track seizures every day.
This Phase 2 trial tests whether adding D-galactose can help people with a confirmed SLC35A2 genetic condition. It aims to improve symptoms such as seizures and ongoing stomach problems like vomiting or diarrhea.
Hear when a new CDKL5 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.